181 related articles for article (PubMed ID: 11504829)
1. Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists.
Christopoulos A; Grant MK; Ayoubzadeh N; Kim ON; Sauerberg P; Jeppesen L; El-Fakahany EE
J Pharmacol Exp Ther; 2001 Sep; 298(3):1260-8. PubMed ID: 11504829
[TBL] [Abstract][Full Text] [Related]
2. 1-(1,2,5-Thiadiazol-4-yl)-4-azatricyclo[2.2.1.0(2,6)]heptanes as new potent muscarinic M1 agonists: structure-activity relationship for 3-aryl-2-propyn-1-yloxy and 3-aryl-2-propyn-1-ylthio derivatives.
Jeppesen L; Olesen PH; Hansen L; Sheardown MJ; Thomsen C; Rasmussen T; Jensen AF; Christensen MS; Rimvall K; Ward JS; Whitesitt C; Calligaro DO; Bymaster FP; Delapp NW; Felder CC; Shannon HE; Sauerberg P
J Med Chem; 1999 Jun; 42(11):1999-2006. PubMed ID: 10354408
[TBL] [Abstract][Full Text] [Related]
3. Muscarinic agonist, (±)-quinuclidin-3-yl-(4-fluorophenethyl)(phenyl)carbamate: High affinity, but low subtype selectivity for human M
Lee NR; Gujarathi S; Bommagani S; Siripurapu K; Zheng G; Dwoskin LP
Bioorg Med Chem Lett; 2019 Feb; 29(3):471-476. PubMed ID: 30554957
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel derivatives of the muscarinic agonist tetra(ethylene glycol)(3-methoxy-1,2,5-thiadiazol-4-yl) [3-(1-methyl-1,2,5,6-tetrahydropyrid-3-yl)-1,2,5-thiadiazol-4-yl] ether (CDD-0304): effects of structural modifications on the binding and activity at muscarinic receptor subtypes and chimeras.
Tejada FR; Nagy PI; Xu M; Wu C; Katz T; Dorsey J; Rieman M; Lawlor E; Warrier M; Messer WS
J Med Chem; 2006 Dec; 49(25):7518-31. PubMed ID: 17149881
[TBL] [Abstract][Full Text] [Related]
5. Function-specific blockage of M(1) and M(3) muscarinic acetylcholine receptors by VX and echothiophate.
Pittel Z; Barak D; Segall Y
Brain Res; 2006 Apr; 1085(1):102-10. PubMed ID: 16580648
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological characterization of 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as muscarinic agonists for the treatment of neurological disorders.
Cao Y; Zhang M; Wu C; Lee S; Wroblewski ME; Whipple T; Nagy PI; Takács-Novák K; Balázs A; Torös S; Messer WS
J Med Chem; 2003 Sep; 46(20):4273-86. PubMed ID: 13678406
[TBL] [Abstract][Full Text] [Related]
7. The interaction of the enantiomers of aceclidine with subtypes of the muscarinic receptor.
Ehlert FJ; Griffin MT; Glidden PF
J Pharmacol Exp Ther; 1996 Dec; 279(3):1335-44. PubMed ID: 8968358
[TBL] [Abstract][Full Text] [Related]
8. Transducer abstraction: a novel approach to the detection of partial agonist efficacy in radioligand binding studies.
Christopoulos A; Grant MK; El-Fakahany EE
J Pharmacol Toxicol Methods; 2000; 43(1):55-67. PubMed ID: 11091130
[TBL] [Abstract][Full Text] [Related]
9. Activation of cerebral function by CS-932, a functionally selective M1 partial agonist: neurochemical characterization and pharmacological studies.
Iwata N; Kozuka M; Hara T; Kanek T; Tonohiro T; Sugimoto M; Niitsu Y; Kondo Y; Yamamoto T; Sakai J; Nagano M
Jpn J Pharmacol; 2000 Nov; 84(3):266-80. PubMed ID: 11138727
[TBL] [Abstract][Full Text] [Related]
10. Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization.
Schwarz RD; Callahan MJ; Coughenour LL; Dickerson MR; Kinsora JJ; Lipinski WJ; Raby CA; Spencer CJ; Tecle H
J Pharmacol Exp Ther; 1999 Nov; 291(2):812-22. PubMed ID: 10525104
[TBL] [Abstract][Full Text] [Related]
11. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors.
Loudon JM; Bromidge SM; Brown F; Clark MS; Hatcher JP; Hawkins J; Riley GJ; Noy G; Orlek BS
J Pharmacol Exp Ther; 1997 Dec; 283(3):1059-68. PubMed ID: 9399977
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the pharmacological antagonism of M2 and M3 muscarinic receptors expressed in isolation and in combination.
Griffin MT; Hsu JC; Shehnaz D; Ehlert FJ
Biochem Pharmacol; 2003 Apr; 65(8):1227-41. PubMed ID: 12694864
[TBL] [Abstract][Full Text] [Related]
13. On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor.
Christopoulos A; Pierce TL; Sorman JL; El-Fakahany EE
Mol Pharmacol; 1998 Jun; 53(6):1120-30. PubMed ID: 9614217
[TBL] [Abstract][Full Text] [Related]
14. In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes.
Watson JM; Hunter AJ; Brown AM; Middlemiss DN
Eur J Pharmacol; 1999 Apr; 370(1):69-77. PubMed ID: 10323282
[TBL] [Abstract][Full Text] [Related]
15. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor.
Olianas MC; Maullu C; Onali P
Br J Pharmacol; 1997 Oct; 122(3):401-8. PubMed ID: 9351494
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor.
Christopoulos A; Parsons AM; El-Fakahany EE
J Pharmacol Exp Ther; 1999 Jun; 289(3):1220-8. PubMed ID: 10336509
[TBL] [Abstract][Full Text] [Related]
17. Dual effects of muscarinic M(2) acetylcholine receptors on the synthesis of cyclic AMP in CHO cells: dependence on time, receptor density and receptor agonists.
Michal P; Lysíková M; Tucek S
Br J Pharmacol; 2001 Mar; 132(6):1217-28. PubMed ID: 11250872
[TBL] [Abstract][Full Text] [Related]
18. Biased Profile of Xanomeline at the Recombinant Human M
McDonald JK; van der Westhuizen ET; Pham V; Thompson G; Felder CC; Paul SM; Thal DM; Christopoulos A; Valant C
ACS Chem Neurosci; 2022 Apr; 13(8):1206-1218. PubMed ID: 35380782
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1.
Langmead CJ; Austin NE; Branch CL; Brown JT; Buchanan KA; Davies CH; Forbes IT; Fry VA; Hagan JJ; Herdon HJ; Jones GA; Jeggo R; Kew JN; Mazzali A; Melarange R; Patel N; Pardoe J; Randall AD; Roberts C; Roopun A; Starr KR; Teriakidis A; Wood MD; Whittington M; Wu Z; Watson J
Br J Pharmacol; 2008 Jul; 154(5):1104-15. PubMed ID: 18454168
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of a novel series of heterobivalent muscarinic ligands based on xanomeline and 1-[3-(4-butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1).
Bonifazi A; Yano H; Del Bello F; Farande A; Quaglia W; Petrelli R; Matucci R; Nesi M; Vistoli G; Ferré S; Piergentili A
J Med Chem; 2014 Nov; 57(21):9065-77. PubMed ID: 25275964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
